Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Plby Group Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Plby Group Inc trades at $1.18 (market cap $136.40M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 58.9× Plby Group Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| BIO | PLBY | |
|---|---|---|
Market Cap | $8.04B | $136.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $2.71 |
52-Week Low | $241.71 | $1.14 |
Enterprise Value | $7.85B | $284.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
PLBY trades at $1.17, up 0.86% today, but remains in a bearish technical trend. The company reported Q1 2026 revenue of $30.2 million with a narrowed net loss of $4.0 million, showing operational improvement. Recent news includes inclusion in Russell indexes and a major share repurchase. Despite negative ROE and high debt, analyst sentiment is positive with 75% buy ratings.
The outlook hinges on continued EBITDA growth and debt management. Opportunities include brand licensing momentum and cost controls. Key risks are persistent net losses, high leverage, and competitive pressures. Investors should weigh analyst optimism against fundamental challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
